Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Novo Nordisk A/S - share repurchase programme
06:46am, Monday, 02'nd Dec 2024
Bagsværd, Denmark, 2 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and C
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger
07:00am, Saturday, 30'th Nov 2024
Data from their most serious competitor, Amgen, suggests the biotech won't upstage the market leaders.
The Score: GM, Macy's, Novo Nordisk and More Stocks That Defined the Week
04:28pm, Friday, 29'th Nov 2024
Here are some of the major companies whose stocks moved on the week's news.
Is Novo Nordisk Stock a Buy?
05:35am, Friday, 29'th Nov 2024
Few companies garner as much reliable attention as Novo Nordisk (NVO) does these days. With a bull market coinciding with a historic run of growth for the Danish pharmaceutical giant related to its GL
Biotech funding has been an issue in the pharmaceutical industry, says Novo Holdings partner
12:17am, Friday, 29'th Nov 2024
Johan Hueffer, senior partner, principal investments at Novo Holdings, discusses investment in life sciences and his macro perspective.
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
10:50am, Wednesday, 27'th Nov 2024
The Biden administration believes that including obesity drugs in Medicare coverage will reduce out-of-pocket costs for the drugs and make them affordable.
Canada approves Novo Nordisk's obesity drug to reduce risk of non-fatal heart attack
07:36am, Wednesday, 27'th Nov 2024
Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or myocardial infarction in some adults, the Danish drugmaker said on Wednesda
Millions more Americans might get access to GLP-1 drugs
04:21pm, Tuesday, 26'th Nov 2024
A new proposal by the Biden administration would see obesity drugs covered under Medicare and Medicaid. Transcript: Conway Gittens: The Dow and the S&P 500 closed at fresh record highs on Tuesday as i
Eli Lilly, Novo Nordisk Stocks Gain as Biden Moves to Expand Coverage of Weight-Loss Drugs
01:20pm, Tuesday, 26'th Nov 2024
Eli Lilly (LLY) and Novo Nordisk (NVO) shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' popular weight-loss drugs in government-backed healthcare plans
Obesity drugmaker stocks gain as Biden proposal expands coverage for anti-obesity medications
12:24pm, Tuesday, 26'th Nov 2024
Shares of obesity drugmakers moved higher on Tuesday after the Biden administration proposed expanded coverage of anti-obesity medications under Medicare and Medicaid. Currently, these programs cover
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
11:33am, Tuesday, 26'th Nov 2024
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs for Americans with Medicare and Medicaid.
Novo Nordisk shares rise as Biden proposes obesity care coverage
07:21am, Tuesday, 26'th Nov 2024
Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Jo Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid.
Novo Nordisk: Supply Strains, Competition, And RFK Concerns Mask Solid Fundamentals
04:20am, Tuesday, 26'th Nov 2024
Novo Nordisk's stock declined 22% over the past six months, influenced by competitive pressures and supply constraints. Eli Lilly's Zepbound is rapidly gaining market share, challenging Novo's dominan
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
06:44pm, Monday, 25'th Nov 2024
Mizuho's Jared Holz joins 'Fast Money' to talk what's next for biopharma space after president-elect Trump names his pick for FDA head.
Novo Nordisk A/S - share repurchase programme
10:16am, Monday, 25'th Nov 2024
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and
